KT&G's Midterm Plan: Doubling Sales by 2027

Feb.02.2023
KT&G's Midterm Plan: Doubling Sales by 2027
KT&G plans to invest $3.1 billion in e-cigarette and ginseng health products and double sales by 2027.

KT&G has recently launched a midterm business plan.


According to the plan, KT&G will invest a total of 3.9 trillion Korean won (3.1 billion US dollars) by 2027, with a focus on its electronic cigarette business (including overseas operations) and health supplements containing ginseng.


KT&G has plans to increase its sales revenue to over 100 trillion Korean won by 2027, a 73% growth compared to the estimated sales revenue of 59 trillion Korean won in 2022.


Bang Kyung-man, the Executive Vice President of KT&G, announced that the company now sells its heated non-combustible cigarette brands in 31 different countries, with a primary focus on the European market. Since partnering with various companies, the sales of its product, "lil," have quadrupled. The company is also considering releasing sales data related to "lil," which has not yet been disclosed due to a partnership agreement with PMI.


The company also presented its business expansion strategy, aiming to obtain more than half of its sales revenue from overseas operations by 2027. It is reported that in 2022, about 33% of KT&G's sales revenue comes from overseas operations.


According to Bang, KT&G is considering Kazakhstan and Eastern Europe as potential locations for a new factory. In order to raise the necessary funds, KT&G may sell some of its real estate assets and borrow from banks.


References:


KT&G has rejected the idea of spinning off its ginseng unit and instead plans to double its sales by 2027.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens has begun selling vape products again in some U.S. stores, marking a notable reversal after the chain pulled vapes from shelves in 2019 amid concerns over youth use and health risks. Juul says it is expanding across thousands of Walgreens locations, and NJOY also lists Walgreens stores as retailers.
Jan.26 by 2FIRSTS.ai
Goyang City Urges Relevant Sellers to Apply for Tobacco Retailer Designation by April 23
Goyang City Urges Relevant Sellers to Apply for Tobacco Retailer Designation by April 23
Goyang Special City in South Korea said it has informed local sellers about the revised Tobacco Business Act, which will take effect on April 24, 2026, and urged them to apply for tobacco retailer designation.
Mar.13 by 2FIRSTS.ai
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Data shows 75% of nations with state stakes in tobacco trade ban modern substitutes compared to 10% in the free-market group. What is driving these divergent regulations?
Feb.04
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
Texas college data show rapid shifts in top vaping brands, with Geek Bar/Vape surging by 2025
A short communication in Drug and Alcohol Dependence examined changes in the most commonly used nicotine vaping brands among Texas college students from 2023 to 2025. The study analyzed 6,049 students aged 18–25 who reported past-30-day nicotine vaping across three repeated cross-sectional spring surveys. The report found that use of Esco Bar, Elf Bar, JUUL, and Puff Bar declined from 2023 to 2025, while Geek Bar/Vape increased.
Feb.27 by 2FIRSTS.ai
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai